The biology of the human natural killer cell

Roder, John; Pross, Hugh F.

doi:10.1007/bf00915064

Cited by 154 publications

(37 citation statements)

References 172 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19,21 NK cells rapidly kill certain target cells without prior immunization or MHC restriction, whose activation is dependent on the balance between inhibitory and activating signals from invariant receptors. [22][23][24] The activating receptors include the cytotoxicity receptors (NCRs) (NKp46, NKp30 and NKp44), C-type lectin receptors (CD94/NKG2C, NKG2D, NKG2E/H and NKG2F) and killer cell immunoglobulin-like receptors (KIRs) (KIR-2DS and KIR-3DS), while the inhibitory receptors include C-type lectin receptors (CD94/NKG2A/B) and KIRs (KIR-2DL and KIR-3DL). Since some structural families contain both activating and inhibitory receptors, trying to understand how NK cell activity is regulated is often complicated.…”

Section: Conception Of Nk Cellsmentioning

confidence: 99%

NK cell-based immunotherapy for malignant diseases

et al. 2013

View full text Add to dashboard Cite

Natural killer (NK) cells play critical roles in host immunity against cancer. In response, cancers develop mechanisms to escape NK cell attack or induce defective NK cells. Current NK cell-based cancer immunotherapy aims to overcome NK cell paralysis using several approaches. One approach uses expanded allogeneic NK cells, which are not inhibited by self histocompatibility antigens like autologous NK cells, for adoptive cellular immunotherapy. Another adoptive transfer approach uses stable allogeneic NK cell lines, which is more practical for quality control and large-scale production. A third approach is genetic modification of fresh NK cells or NK cell lines to highly express cytokines, Fc receptors and/or chimeric tumor-antigen receptors. Therapeutic NK cells can be derived from various sources, including peripheral or cord blood cells, stem cells or even induced pluripotent stem cells (iPSCs), and a variety of stimulators can be used for large-scale production in laboratories or good manufacturing practice (GMP) facilities, including soluble growth factors, immobilized molecules or antibodies, and other cellular activators. A list of NK cell therapies to treat several types of cancer in clinical trials is reviewed here. Several different approaches to NK-based immunotherapy, such as tissue-specific NK cells, killer receptor-oriented NK cells and chemically treated NK cells, are discussed. A few new techniques or strategies to monitor NK cell therapy by non-invasive imaging, predetermine the efficiency of NK cell therapy by in vivo experiments and evaluate NK cell therapy approaches in clinical trials are also introduced.

show abstract

Section: Conception Of Nk Cellsmentioning

confidence: 99%

NK cell-based immunotherapy for malignant diseases

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Since this "natural" killer activity is most evident against neoplastic and virus-infected targets, it is thought that the major in vivo role of NK cells is to provide surveillance against neoplastic cells or those modified by viral infection (1). NK activity can be readily detected in blood of normal individuals and is known to be altered in a variety of disorders (2).…”

mentioning

confidence: 99%

Natural killer cells are present in the normal human lung but are functionally impotent.

Robinson¹,

Pinkston²,

Crystal³

1984

J. Clin. Invest.

119

View full text Add to dashboard Cite

“…NK cells can rapidly kill certain target cells, including tumor cells with downregulated MHC class Ⅰ molecules [21] . Thus, NK cells play a critical role in antitumor immunity.…”

Section: Natural Killer Cellsmentioning

confidence: 99%

Immunotherapy in Colorectal Cancer

Mak¹,

Moschetta²,

Arkenau³

2016

Colorectal Cancer - From Pathogenesis to Treatment

View full text Add to dashboard Cite

The incidence of colorectal cancer (CRC) is on the rise, and the prognosis for patients with recurrent or metastatic disease is extremely poor. Although chemotherapy and radiation therapy can improve survival rates, it is imperative to integrate alternative strategies such as immunotherapy to improve outcomes for patients with advanced CRC. In this review, we will discuss the effect of immunotherapy for inducing cytotoxic T lymphocytes and the major immunotherapeutic approaches for CRC that are currently in clinical trials, including peptide vaccines, dendritic cell-based cancer vaccines, whole tumor cell vaccines, viral vector-based cancer vaccines, adoptive cell transfer therapy, antibody-based cancer immunotherapy, and cytokine therapy. The possibility of combination therapies will also be discussed along with the challenges presented by tumor escape mechanisms.© 2013 Baishideng Publishing Group Co., Limited. All rights reserved.Key words: Colorectal cancer; Cytotoxic T lymphocyte; Dendritic cell; Immunotherapy; vaccine Core tip: The prognosis for patients with recurrent or metastatic colorectal cancer (CRC) is extremely poor. Immunotherapy may be effective for treating CRC patients and/or preventing relapse. The immunotherapeutic approaches for CRC, including peptide vaccines, dendritic cell-based cancer vaccines, whole tumor cell vaccines, viral vector-based cancer vaccines, adoptive cell transfer therapy, antibody-based cancer immunotherapy, and cytokine therapy have been demonstrated. The blockade of multiple immune regulatory checkpoints combined with immunotherapy and/or conventional chemotherapy may be effective in treating patients with advanced CRC.

show abstract

The biology of the human natural killer cell

Cited by 154 publications

References 172 publications

NK cell-based immunotherapy for malignant diseases

NK cell-based immunotherapy for malignant diseases

Natural killer cells are present in the normal human lung but are functionally impotent.

Immunotherapy in Colorectal Cancer

Contact Info

Product

Resources

About